AU2016367712B2 - Immunomodulating composition for treatment - Google Patents

Immunomodulating composition for treatment Download PDF

Info

Publication number
AU2016367712B2
AU2016367712B2 AU2016367712A AU2016367712A AU2016367712B2 AU 2016367712 B2 AU2016367712 B2 AU 2016367712B2 AU 2016367712 A AU2016367712 A AU 2016367712A AU 2016367712 A AU2016367712 A AU 2016367712A AU 2016367712 B2 AU2016367712 B2 AU 2016367712B2
Authority
AU
Australia
Prior art keywords
hpv
sequence
codon
construct
coding sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016367712A
Other languages
English (en)
Other versions
AU2016367712A1 (en
Inventor
Julie Dutton
Ian Frazer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jingang Medicine Australia Pty Ltd
Original Assignee
Jingang Medicine Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015905099A external-priority patent/AU2015905099A0/en
Application filed by Jingang Medicine Australia Pty Ltd filed Critical Jingang Medicine Australia Pty Ltd
Publication of AU2016367712A1 publication Critical patent/AU2016367712A1/en
Assigned to JINGANG MEDICINE (AUSTRALIA) PTY LTD reassignment JINGANG MEDICINE (AUSTRALIA) PTY LTD Request for Assignment Assignors: ADMEDUS VACCINES PTY LTD
Application granted granted Critical
Publication of AU2016367712B2 publication Critical patent/AU2016367712B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2016367712A 2015-12-09 2016-12-09 Immunomodulating composition for treatment Active AU2016367712B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015905099A AU2015905099A0 (en) 2015-12-09 Immunomodulating composition for treatment
AU2015905099 2015-12-09
PCT/AU2016/051214 WO2017096432A1 (en) 2015-12-09 2016-12-09 Immunomodulating composition for treatment

Publications (2)

Publication Number Publication Date
AU2016367712A1 AU2016367712A1 (en) 2018-06-14
AU2016367712B2 true AU2016367712B2 (en) 2021-10-07

Family

ID=59012459

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016367712A Active AU2016367712B2 (en) 2015-12-09 2016-12-09 Immunomodulating composition for treatment

Country Status (8)

Country Link
US (1) US10596248B2 (enExample)
EP (1) EP3386593A4 (enExample)
JP (1) JP7110108B2 (enExample)
KR (1) KR102895580B1 (enExample)
CN (1) CN108601951B (enExample)
AU (1) AU2016367712B2 (enExample)
CA (1) CA3006779A1 (enExample)
WO (1) WO2017096432A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3092937A1 (en) 2018-03-06 2019-09-12 PGEN Therapeutics, Inc. Human papillomavirus vaccines and uses of the same
WO2019173463A1 (en) 2018-03-06 2019-09-12 Intrexon Corporation Hepatitis b vaccines and uses of the same
CN113498439A (zh) * 2018-12-20 2021-10-12 波赛达治疗公司 纳米转座子组合物及使用方法
CA3217457A1 (en) * 2021-05-06 2022-11-10 Spyro Mousses Multitargeting rna immunotherapy compositions
CN114134165B (zh) * 2022-01-27 2022-04-29 北京循生生物医学研究有限公司 一种新型hpv治疗性核酸疫苗
WO2024131833A1 (en) * 2022-12-21 2024-06-27 Abogen Biosciences (Shanghai) Co., Ltd. Mrna-based hpv+ cancer vaccines, and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016636A1 (en) * 1991-03-14 1992-10-01 Cantab Pharmaceuticals Research Limited Recombinant virus vectors encoding human papillomavirus proteins
WO1996019496A1 (en) * 1994-12-20 1996-06-27 Csl Limited Variants of human papilloma virus antigens
WO2009049350A1 (en) * 2007-10-15 2009-04-23 The University Of Queensland Expression system for modulating an immune response

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US606909A (en) 1898-07-05 barnard
US417671A (en) 1889-12-17 Henry esbach
US4184917A (en) 1974-04-01 1980-01-22 Sandoz Ltd. Process for producing a structurally modified interferon
US4321365A (en) 1977-10-19 1982-03-23 Research Corporation Oligonucleotides useful as adaptors in DNA cloning, adapted DNA molecules, and methods of preparing adaptors and adapted molecules
US4293652A (en) 1979-05-25 1981-10-06 Cetus Corporation Method for synthesizing DNA sequentially
US4351901A (en) 1980-03-24 1982-09-28 Cetus Corporation Method for single nucleotide alteration
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
DE10399032I1 (de) 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
US5179022A (en) 1988-02-29 1993-01-12 E. I. Du Pont De Nemours & Co. Biolistic apparatus for delivering substances into cells and tissues in a non-lethal manner
WO1990009441A1 (en) 1989-02-01 1990-08-23 The General Hospital Corporation Herpes simplex virus type i expression vector
GB8923123D0 (en) 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
EP0500799B1 (en) 1989-11-16 1998-01-14 Duke University Particle mediated transformation of animal skin tissue cells
FR2658432B1 (fr) 1990-02-22 1994-07-01 Medgenix Group Sa Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation.
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
AU665176B2 (en) 1990-09-21 1995-12-21 Novartis Vaccines And Diagnostics, Inc. Packaging cells
WO1992014829A1 (en) 1991-02-19 1992-09-03 The Regents Of The University Of California Viral particles having altered host range
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
AU3972893A (en) 1992-04-03 1993-11-08 Baylor College Of Medicine Gene therapy using the intestine
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5831005A (en) 1992-09-24 1998-11-03 Chiron Corporation Synthesis of N-substituted oligomers
WO1994012629A1 (en) 1992-12-02 1994-06-09 Baylor College Of Medicine Episomal vectors for gene therapy
US5654186A (en) 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
DE69420033T2 (de) 1993-04-06 1999-12-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Bethesda Gibbon leukemia virus retrovirale vektoren
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
US6140087A (en) 1993-06-24 2000-10-31 Advec, Inc. Adenovirus vectors for gene therapy
US6120764A (en) 1993-06-24 2000-09-19 Advec, Inc. Adenoviruses for control of gene expression
US5834441A (en) 1993-09-13 1998-11-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Adeno-associated viral (AAV) liposomes and methods related thereto
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
JPH09510601A (ja) 1993-11-12 1997-10-28 ケース・ウエスタン・リザーブ・ユニバーシティ ヒト遺伝子治療用のエピソーム発現ベクター
ES2192573T3 (es) 1994-01-21 2003-10-16 Powderject Vaccines Inc Instrumento de deposito de genes mediante arrastre gaseoso.
US5731172A (en) 1994-03-09 1998-03-24 Sumitomo Pharmaceuticals Company, Ltd. Recombinant adenovirus and process for producing the same
ATE334216T1 (de) 1994-04-29 2006-08-15 Pharmacia & Upjohn Co Llc Impstoff gegen felines immunodefizienz-virus
US5604090A (en) 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US5693508A (en) 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
US5656611A (en) 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
JP3770333B2 (ja) 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えｄｎａウイルスおよびその製造方法
GB9506782D0 (en) 1995-04-01 1995-05-24 British Biotech Pharm Retroviral vectors
WO1997008298A1 (en) 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
JP2000506727A (ja) 1996-03-05 2000-06-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 組換え生ネコ免疫不全ウイルスおよびプロウイルスｄｎａワクチン
US5952221A (en) 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
KR100556864B1 (ko) 1997-05-13 2006-03-10 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 렌티바이러스-기원 유전자 전달 벡터
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
WO2000000600A2 (en) 1997-09-22 2000-01-06 Chang Lung Ji Lentiviral vectors, comprising modified major donor splice sites and major packaging signals
WO1999015641A1 (en) 1997-09-24 1999-04-01 The Regents Of The University Of California Non-primate lentiviral vectors and packaging systems
US7048929B1 (en) 1997-11-10 2006-05-23 Dana-Farber Cancer Institute, Inc. Stabilized primate lentivirus envelope glycoproteins
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
AU749059B2 (en) 1997-12-12 2002-06-20 Cell Genesys, Inc. Therapeutic use of lentiviral vectors
WO1999051754A1 (en) 1998-04-02 1999-10-14 Dana-Farber Cancer Institute, Inc. Infectious pseudotyped lentiviral vectors lacking matrix protein and uses thereof
ATE549032T1 (de) 1999-03-26 2012-03-15 Vical Inc Adjuvanzverbindungen zur verbesserung von immunreaktionen auf polynukleotid-basierten impfstoffen
CA2760534A1 (en) 1999-04-14 2000-10-19 Novartis Vaccines And Diagnostics, Inc. Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US7250299B1 (en) 1999-04-29 2007-07-31 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
JP2003509035A (ja) 1999-09-16 2003-03-11 ザイコス インク． ポリエピトープポリペプチドをコードする核酸
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
WO2001081609A2 (en) 2000-03-22 2001-11-01 Chiron Corporation Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
US6875748B2 (en) 2000-04-21 2005-04-05 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
ATE499948T1 (de) 2001-01-12 2011-03-15 Novartis Vaccines & Diagnostic Nukleinsäure mukosale immunisierung
DE60126737T2 (de) * 2001-03-23 2007-11-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modifizierte HPV E6- und E7-Gene und -Proteine als Impfstoff
US7531180B2 (en) 2001-05-31 2009-05-12 Novartis Vaccines And Diagnostics, Inc Chimeric alphavirus replicon particles
US7897380B2 (en) 2002-08-29 2011-03-01 The Board Of Trustees Of The Leland Stanford Junior University Circular nucleic acid vectors, and methods for making and using the same
JP5345053B2 (ja) * 2006-04-19 2013-11-20 浦項工科大學校 産學協力團 子宮頸癌の予防及び治療のためのヒトパピローマウイルスポリペプチドと免疫増強剤を含む組成物
US9050287B2 (en) * 2009-01-23 2015-06-09 The Trustees Of The University Of Pennsylvania Vaccines for human papilloma virus and methods for using the same
EP2604629B1 (en) * 2010-08-13 2018-02-28 Genexine, Inc. Composition for preventing or treating cervical cancer having human papillomavirus immunity enhancer
KR101206514B1 (ko) * 2012-08-10 2012-11-30 서석윤 완충성이 우수한 목발
CN103772508B (zh) * 2014-01-15 2017-05-10 深圳泰来生物医药有限公司 免疫增强的人乳头瘤病毒感染及相关疾病的治疗性疫苗
JP6724853B2 (ja) * 2017-04-24 2020-07-15 アイシン精機株式会社 駐車支援装置

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016636A1 (en) * 1991-03-14 1992-10-01 Cantab Pharmaceuticals Research Limited Recombinant virus vectors encoding human papillomavirus proteins
WO1996019496A1 (en) * 1994-12-20 1996-06-27 Csl Limited Variants of human papilloma virus antigens
WO2009049350A1 (en) * 2007-10-15 2009-04-23 The University Of Queensland Expression system for modulating an immune response
US20110020374A1 (en) * 2007-10-15 2011-01-27 The University Of Queensland Expression system for modulating an immune response

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRAVO et al., "Codon usage in papillomavirus genes: practical and functional aspects'';", Papillomavirus Report, (2005-03-01), vol. 16, no. 2, doi:10.1179/095741905X24996, pages 63 - 72 *
JULIE L. DUTTON, LI BO, WOO WAI-PING, MARSHAK JOSHUA O., XU YAN, HUANG MEEI-LI, DONG LICHUN, FRAZER IAN H., KOELLE DAVID M.: "A Novel DNA Vaccine Technology Conveying Protection against a Lethal Herpes Simplex Viral Challenge in Mice", PLOS ONE, vol. 8, no. 10, pages e76407, XP055390171, DOI: 10.1371/journal.pone.0076407 *
KONG-NAN ZHAO, JIEZHONG CHEN: "Codon usage roles in human papillomavirus : Genetic codons and papillomavirus", REVIEWS IN MEDICAL VIROLOGY, CHICHESTER, GB, vol. 21, no. 6, 1 November 2011 (2011-11-01), GB, pages 397 - 411, XP055390172, ISSN: 1052-9276, DOI: 10.1002/rmv.707 *
LIU WEN JUN, ET AL: "Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity.", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 301, no. 1, 15 September 2002 (2002-09-15), AMSTERDAM, NL, pages 43 - 52, XP002605647, ISSN: 0042-6822, DOI: 10.1006/VIRO.2002.1584 *
LIU, W.J. ; ZHAO, K.N. ; GAO, F.G. ; LEGGATT, G.R. ; FERNANDO, G.J. ; FRAZER, I.H.: "Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 20, no. 5-6, 12 December 2001 (2001-12-12), AMSTERDAM, NL, pages 862 - 869, XP027303791, ISSN: 0264-410X *
ZHOU JIAN ET AL, JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, (1999-06-01), vol. 73, no. 6, ISSN 0022-538X, pages 4972 - 4982 *

Also Published As

Publication number Publication date
JP7110108B2 (ja) 2022-08-01
EP3386593A4 (en) 2019-07-24
WO2017096432A1 (en) 2017-06-15
KR20180083437A (ko) 2018-07-20
US10596248B2 (en) 2020-03-24
CN108601951A (zh) 2018-09-28
AU2016367712A1 (en) 2018-06-14
CN108601951B (zh) 2022-11-22
CA3006779A1 (en) 2017-06-15
EP3386593A1 (en) 2018-10-17
US20190134181A1 (en) 2019-05-09
KR102895580B1 (ko) 2025-12-03
JP2019505567A (ja) 2019-02-28

Similar Documents

Publication Publication Date Title
AU2016367712B2 (en) Immunomodulating composition for treatment
JP5872755B2 (ja) 抗ｈｓｖ−２ワクチン接種のための組成物および方法
CN111995664B (zh) 用于治疗巨细胞病毒的组合物和方法
EP1587816B1 (en) Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
US9592285B2 (en) Vaccines against multiple subtypes of influenza virus
US20180186839A1 (en) Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using same
US20250339510A1 (en) Polynucleotide vaccine formulations and methods of using the same
US9795658B2 (en) Expression system for modulating an immune response
US20220184200A1 (en) Virus-like particles and uses thereof
US20170224808A1 (en) Therapeutic compositiojns and methods for inducing an immune response to herpes simplex virus type 2 (hsv-2)
US9060984B2 (en) Recombinant HIV-1 envelope proteins comprising stabilizing two-cysteine mini-domains in gp41
US20120039935A1 (en) Methods of treating measles infectious disease in mammals
EP4612305A1 (en) Binary self-amplifying nucleic acid platform and uses thereof
WO2024243675A1 (en) Compositions of mrna-encoded virus-like particles, compositions of mrna-lipid nanoparticles, and methods for use thereof
Rainone ROLE OF THE MUCOSAE-ASSOCIATED EPITHELIAL CHEMOKINE (MEC/CCL28) IN THE MODULATION OF THE IMMUNE RESPONSE AGAINST VIRAL INFECTIONS
WO2000025820A1 (en) Compounds and methods for genetic immunization

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: JINGANG MEDICINE (AUSTRALIA) PTY LTD

Free format text: FORMER APPLICANT(S): ADMEDUS VACCINES PTY LTD

FGA Letters patent sealed or granted (standard patent)